Truist Financial Corp Sells 890 Shares of BioNTech SE (NASDAQ:BNTX)

Truist Financial Corp lessened its stake in shares of BioNTech SE (NASDAQ:BNTX) by 26.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,519 shares of the company’s stock after selling 890 shares during the period. Truist Financial Corp’s holdings in BioNTech were worth $287,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in BNTX. Planning Capital Management Corp grew its stake in shares of BioNTech by 45,000.0% in the third quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock worth $54,000 after acquiring an additional 450 shares during the last quarter. GAMMA Investing LLC raised its position in shares of BioNTech by 48.2% in the 4th quarter. GAMMA Investing LLC now owns 923 shares of the company’s stock worth $105,000 after purchasing an additional 300 shares during the last quarter. AlphaCentric Advisors LLC bought a new position in BioNTech in the 4th quarter worth about $168,000. Harbor Advisors LLC purchased a new stake in BioNTech during the 3rd quarter valued at about $238,000. Finally, Freedom Investment Management Inc. bought a new stake in BioNTech during the 3rd quarter valued at about $243,000. Hedge funds and other institutional investors own 15.52% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and issued a $150.00 target price on shares of BioNTech in a research note on Monday, November 18th. BMO Capital Markets reaffirmed an “outperform” rating on shares of BioNTech in a research report on Monday, December 2nd. Truist Financial started coverage on BioNTech in a report on Friday, January 10th. They issued a “buy” rating and a $172.00 target price for the company. Berenberg Bank began coverage on BioNTech in a report on Tuesday, November 19th. They set a “buy” rating and a $130.00 price target on the stock. Finally, Evercore ISI upgraded BioNTech from an “in-line” rating to an “outperform” rating and lifted their price objective for the stock from $110.00 to $125.00 in a report on Tuesday, November 19th. Three research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $142.72.

BioNTech Stock Performance

BNTX opened at $114.77 on Thursday. The company’s 50 day moving average is $117.07 and its 200 day moving average is $112.47. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. The company has a market cap of $27.51 billion, a price-to-earnings ratio of -54.65 and a beta of 0.30. BioNTech SE has a 12-month low of $76.53 and a 12-month high of $131.49.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.